

1 **Pneumococcal conjugate vaccine coverage and indirect protection against invasive**
2 **pneumococcal disease and pneumonia hospitalisations in Australia: a retrospective record**
3 **linkage cohort study**
4

5 Authors:

6 Jocelyn Chan^{1,2}, Heather F Gidding^{3,4,5}, Christopher C Blyth⁶, Parveen Fathima⁷, Sanjay Jayasinghe^{5,8}, Peter B
7 McIntyre⁵, Hannah C Moore⁷, Kim Mulholland^{1,2,9}, Cattram D Nguyen^{1,2}, Ross Andrews^{10,11}, Fiona M Russell^{1,2}

8

- 9 1. Asia-Pacific Health Research Group, Murdoch Children’s Research Institute, Melbourne, Australia.
10 2. Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
11 3. Northern Clinical School, The University of Sydney, Sydney Australia
12 4. Women and Babies Health Research, Kolling Institute, Northern Sydney Local Health District, Sydney
13 Australia
14 5. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The
15 Children's Hospital at Westmead, Sydney, Australia
16 6. School of Medicine, University of Western Australia, Perth, Australia.
17 7. Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western
18 Australia, Perth, Australia.
19 8. Children’s Hospital at Westmead Clinical School, Faculty of Medicine, University of Sydney, Sydney,
20 Australia
21 9. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine,
22 London, United Kingdom.
23 10. Global & Tropical Health Division, Menzies School of Health Research, Charles Darwin University,
24 Darwin, Australia
25 11. National Centre for Epidemiology & Population Health, Australian National University, Canberra,
26 Australian Capital Territory, Australia
27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract**

2 **Background:**

3 There is limited empiric evidence on the coverage of pneumococcal conjugate vaccines (PCV) required to
4 generate substantial indirect protection. We investigate the association between population PCV coverage and
5 indirect protection against invasive pneumococcal disease (IPD) and pneumonia hospitalisations among under-
6 vaccinated Australian children.

7 **Methods:**

8 Birth and vaccination records, IPD notifications and hospitalisations were individually linked for children aged
9 < five years, born between 2001 and 2012 in two Australian states (New South Wales and Western Australia;
10 1.37 million children). Using Poisson regression models, we examined the association between PCV coverage,
11 in small geographical units, and the incidence of (1) 7-valent PCV (PCV7)-type IPD, (2) all-cause pneumonia
12 and (3) pneumococcal and lobar pneumonia hospitalisation in under-vaccinated children. Under-vaccinated
13 children received < two doses of PCV at < 12 months of age and no doses at \geq 12 months of age. Potential
14 confounding variables were selected for adjustment *a priori* with the assistance of a directed acyclic graph. The
15 main limitations of this study include the potential for differential loss to follow-up, geographical
16 misclassification of children (based on addressed at birth only) and unmeasured confounders.

17 **Findings**

18 There were strong inverse associations between PCV coverage and the incidence of PCV7-type IPD (adjusted
19 incidence rate ratio [aIRR] 0.967, 95% CI 0.958-0.975, p-value <0.001), and pneumonia hospitalisations (all-
20 cause pneumonia: aIRR 0.991 95% CI 0.990-0.994, p-value<0.001) among under-vaccinated children.
21 Subgroup analyses for children < four months old, urban, rural and Indigenous populations showed similar
22 trends, although effects were smaller for rural and Indigenous populations. Fifty-percent coverage of PCV7
23 among children < five years of age prevented up to 72.5% (95% CI 51.6-84.4) of PCV7-type IPD among
24 under-vaccinated children, while 90% coverage prevented 95.2% (95% CI 89.4-97.8).

25 **Conclusions**

26 In this study we observed substantial indirect protection at low PCV coverage, challenging assumptions high
27 vaccine coverage is required.

28 **Author summary**

29 **Why was this study done?**

- 30 • Pneumococcal conjugate vaccines (PCVs) reduce the burden of pneumococcal disease in vaccinated
31 and unvaccinated populations through both direct and indirect (herd) effects.

- 1 • The indirect effects comprise a substantial component of overall vaccine impact, contributing to the
2 cost-effectiveness of the vaccine but little is known about what factors contribute to herd protection,
3 including vaccination coverage.
- 4 • In this study, we examined association between PCV coverage and indirect effects within in diverse
5 populations within Australia

6 **What did the researchers do and find?**

- 7 • Using a large dataset of 1.3 million children from two states in Australia, we quantified the relationship
8 between PCV coverage within small geographical units and indirect protection against pneumococcal
9 disease. We also performed similar analyses for infants too young to be fully vaccinated, urban, rural
10 and Indigenous populations.
- 11 • There were strong inverse relationships between PCV coverage and the incidence of severe invasive
12 disease due to vaccine types and pneumonia hospitalisations among under-vaccinated children i.e.
13 higher coverage were associated with greater reductions in disease due to indirect effects. We also
14 found substantial indirect effects at relatively low levels of PCV coverage. We estimated that 50% and
15 90% coverage of 7-valent PCV (PCV7) among children under five years of age prevented almost three-
16 quarters (72.5%, 95% CI 51.6-84.4) and almost all (95.2%, 95% CI 89.4-97.8) of PCV7-type severe
17 invasive disease, respectively. For pneumonia, we estimated that 50% and 90% coverage was sufficient
18 to prevent one-third (33.3%, 95% CI 27.3-38.8) and about half (51.7%, 95% CI 43.7-58.6) of all-cause
19 pneumonia hospitalisations among under-vaccinated children.
- 20 • These trends were similar for children less than four months old, urban, rural and Indigenous
21 populations, although these effects were smaller for rural and Indigenous populations. There was also a
22 trend towards decreasing incidence of PCV13-type IPD among under-vaccinated children as PCV13
23 coverage increased.

24 **What do these findings mean?**

- 25 • Our results challenge existing assumptions that high PCV coverage is required to achieve substantial
26 indirect protection.
- 27 • Understanding the determinants of indirect effects are particularly urgent as countries that have
28 controlled vaccine-type pneumococcal disease consider using reducing the number of PCV doses (from
29 three to two). Reduced dose schedules have the potential to significantly lower program costs while
30 maintaining vaccine impact, providing indirect protection is achieved and preserved.

31 **Introduction**

32 Infections due to *Streptococcus pneumoniae*, the pneumococcus, are a leading cause of morbidity and mortality
33 among children globally [1]. Pneumococcal conjugate vaccines (PCVs) have been successful in reducing
34 pneumococcal disease through the direct protection of vaccinated individuals and indirect protection of both

1 vaccinated and unvaccinated individuals [2]. Following the introduction of PCV to childhood immunisation
2 schedules, many high-income countries, including Australia, have observed the near elimination of vaccine-
3 type (VT) invasive pneumococcal disease with impacts extending beyond targeted age groups due to reduced
4 transmission of VT pneumococci [3–5].

5 The 13-valent PCV (Pneumovax 13, Pfizer) and 10-valent PCV (Synflorix, GSK) are costly and infant
6 immunisation schedules are becoming increasingly crowded due to multiple vaccines. Therefore a PCV
7 schedule comprising only two doses as opposed to three or four doses, once vaccine-types have been
8 controlled, is an attractive policy option [6]. In 2020, the UK became the first country to move to a two dose
9 (1+1) schedule for 13-valent PCV (PCV13) in the childhood vaccination program [7]. However, evidence to
10 support the use of 1+1 schedules in settings with low or heterogenous vaccine coverage is not available.

11 Conceptually, indirect effects are achieved through sufficient vaccination coverage among age groups primarily
12 responsible for transmission [8]. With sufficient indirect effects, near elimination of VT transmission and
13 disease can be achieved. Near-elimination of VT disease has largely occurred in settings that have rapidly
14 reached very high rates of coverage, hence it is often assumed that high PCV coverage is required to achieve
15 elimination but there is limited evidence for this [9]. Settings with lower rates of coverage often lack the
16 disease surveillance required to demonstrate indirect effects. It is therefore not clear whether VT elimination is
17 possible for nearly half of the countries that have introduced PCV, which have less than 90% PCV coverage
18 [10]. To date, most studies evaluating indirect effects from PCV have used aggregate data and ecological study
19 designs, such as before-and-after or time-series analyses. Few have incorporated PCV coverage into their
20 analyses.

21 Australia is a geographically diverse setting with a combination of dense urban populations and sparsely
22 populated rural areas. Within Australia, Aboriginal and Torres Strait Islander children (henceforth referred to as
23 Indigenous children), experience significantly higher rates of morbidity across a range of infectious diseases
24 including pneumococcal disease, likely related to higher levels of social disadvantage [11,12]. Pre-PCV
25 introduction, invasive pneumococcal disease rates in Indigenous children from Central Australia, were some of
26 the highest in the world [13].

27 In June 2001, 7-valent PCV (PCV7) was introduced for high risk children, including Indigenous children and
28 children with specified medical conditions, at ages two, four and six months. Children who were medically at
29 risk received a fourth dose of PCV7 at 12 months and a dose of 23-valent pneumococcal polysaccharide
30 vaccine (PPV23) at 5 years of age, while Indigenous children in high-incidence jurisdictions received PPV23 at
31 18-24 months of age. A three-dose PCV program (2, 4 and 6 months) became universal in January 2005, with
32 catch-up doses for children aged less than two years of age. In July 2011, PCV13 replaced PCV7 with a catch-
33 up program funding a supplemental dose of PCV13 for children 12-35 months of age [14]. For Indigenous
34 children in high-incidence jurisdictions, a fourth dose of PCV13 replaced the PPV23 vaccine at 18-23 months.

1 Using the same large linked immunisation and hospitalisation dataset, indirect protection following PCV
2 introduction previously in Australia has been reported previously at the State level for children less than two
3 years of age, register with all-cause pneumonia declining among unvaccinated Indigenous (12% reduction; 95%
4 CI 3-25) and non-Indigenous children (45% reduction; 95% CI 41-49) [15].

5 In this study, we extended this analysis by examining the association between PCV coverage in small
6 geographic units within two states for both incidence of invasive pneumococcal disease (IPD) and hospitalised
7 pneumonia among under-vaccinated children, in periods when coverage was changing rapidly. Our study
8 provides a unique opportunity to evaluate indirect protection against pneumococcal disease in the absence of
9 the widespread use of the booster dose making this analysis more applicable to many low-income countries
10 where, at the time of the study, the 3+0 schedule is primarily used [16].

11 **Methods**

12 **Study design**

13 Our study design was a retrospective population-based cohort that used a subset of children under five years of
14 age from a dataset of all children born in New South Wales (NSW) and Western Australia (WA) between 2001
15 and 2012, a combined birth cohort of approximately 1.37 million.[17]. Birth records were probabilistically
16 linked (using name, date of birth, residential address and sex) to health data including vaccination register , IPD
17 notification data and hospitalisation data [17].

18 **Linked data sources**

19 Vaccination status was obtained from the Australian Childhood Immunisation Register (ACIR), which includes
20 all children enrolled in the publicly funded healthcare system and comprises ~99% of children in Australia by
21 age 12 months [18]. IPD cases, defined as isolation of *S. pneumoniae* by culture or detection of nucleic acid
22 from a normally sterile, are notified as part of state-based passive surveillance systems [18]. Hospitalisation
23 data covered all inpatient separations (discharges, transfers and deaths) and included primary diagnosis, and up
24 to 50 (NSW) or 20 (WA) secondary diagnoses (coded using the Australian version of the International
25 Classification of Diseases [ICD-AM] coding system). IPD data was available from January 2001 onwards,
26 while hospitalisation data were available from July 2001 onwards. Demographic and health risk factor data
27 were obtained from state perinatal data collection and birth registries (S1 File, Table 1) [18]. See S1 File (Fig 1)
28 for a flow chart of the study cohort and data sources.

29 **Study definitions**

30 PCV7-type IPD was defined as IPD due to serotypes in PCV7 i.e. serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.
31 PCV13, non-PCV7 type IPD, was defined as IPD due to the additional 6 serotypes in PCV13 i.e. serotypes 1, 3,
32 5, 6A, 7F and 19A. For all-cause pneumonia, we identified all hospitalisations with a pneumonia-related
33 diagnostic code in the principal or additional diagnosis fields. Pneumococcal or lobar pneumonia
34 hospitalisations were restricted to hospitalisations coded as either pneumococcal pneumonia (J13) or lobar

1 pneumonia (J18.1) (S1 File, Table 2). Inter-hospital transfers and admissions within 14 days of a previous
2 separation date were merged and classified as a single episode as per previous analyses [19]. All outcomes were
3 evaluated for children under five years of age.

4 We defined a child as vaccinated with PCV if they received an adequate number of doses to develop a
5 protective immune response against vaccine serotypes at least 14 days prior to onset of any study outcomes i.e.
6 two or more PCV doses administered at less than 12 months of age, or at least one PCV dose administered after
7 the age of 12 months [20]. Otherwise cases were classified as under-vaccinated. Given children who have
8 received one dose of PCV at less than 12 months of age may have partial protection, we have also completed
9 sensitivity analyses examining indirect effects among completely unvaccinated children (S1 File, Tables 14 and
10 15).

11 **Statistical analyses**

12 For descriptive analyses of PCV coverage over time, we calculated and graphed coverage among children less
13 than five years of age at three-monthly intervals (31 March, 30 June, 30 September and 31 December) from
14 2001 to 2012. For example, PCV coverage among children less than five years of age at the final quarter of
15 2012 (assessed at 31 December), would be calculated for those born between 31 December 2007 and 30
16 December 2012. Coverage was calculated among children under five years of age to aid comparison with
17 previous studies [21,22] and because previous research suggests that vaccination of children up to five years of
18 age are key for the generation of indirect effects [21,23].

19 To visualise any geographic heterogeneity in PCV coverage, PCV coverage was mapped within Statistical
20 Local Areas among children under five years of age at three time points – December 2005, December 2009 and
21 December 2012. The three time points were chosen to represent the early post-PCV7 period, the late post-
22 PCV7 period and the early PCV13 period. Statistical Local Areas (SLA) are the second smallest geographical
23 spatial unit used by the Australian Bureau of Statistics [24]. In NSW and WA, there are 199 and 155 SLAs,
24 respectively. SLAs vary in population size from less than 100 children in some rural areas to around 11 000
25 children under five years of age in urban areas. SLAs with fewer than 100 children under five years of age were
26 excluded to enable meaningful estimates of PCV coverage for the different age groups.

27 Crude rates of IPD and pneumonia hospitalisation among all children and under-vaccinated children under five
28 years of age over three time periods were calculated: targeted PCV program (2001-04), universal PCV7
29 program (2005-10) and universal PCV13 program (2011-12). Person-time for each child started at birth and
30 was censored at the earliest of the following: death, when the child reached five years of age or at the end of the
31 study period. For the under-vaccinated group, person-time was also censored when the child was considered
32 vaccinated as previously defined.

33 To determine the association between PCV coverage and indirect effects against IPD and hospitalised
34 pneumonia (primary analysis), we first calculated the incidence of each disease outcome during the person-time
35 for which children were under-vaccinated up to five years of age. We divided each child's under-vaccinated

1 person-time into successive three-month intervals and linked the intervals to PCV coverage in their SLA of
2 residence at that same time period. SLA of residence was based on mother's residence at child's birth. Using
3 Poisson regression models, we examined the association between SLA-level PCV coverage and disease
4 incidence in under-vaccinated children. We used robust variance estimates to account for clustering,
5 accommodating multiple coverage estimates for each individual and checked linearity assumptions by plotting
6 the log of the disease rates against PCV coverage.

7 Analyses relating to PCV7-type IPD used the full study period from January 2001 and December 2012, while
8 analyses relating to PCV13, non-PCV7-type IPD were restricted to from January 2009 onwards –18 months
9 prior to PCV13 introduction. Analyses relating to pneumonia hospitalisations used data from July 2001
10 onwards due to lack of availability of hospitalisation data in NSW prior to this date.

11 Potential confounding variables were selected *a priori* using a directed acyclic graph (DAG), informed by
12 relevant literature and refined through expert consultation (S1 File, pp 6). These were age group, calendar year,
13 Indigenous status, season, Index of Relative Socio-economic Advantage and Disadvantage (IRSAD) score,
14 Accessibility or Remoteness Index of Australia (ARIA) category, birth weight, gestational age, maternal
15 smoking during pregnancy, number of previous pregnancies, and previous hospitalisation with an ICD code
16 corresponding to the presence of a medical condition increasing risk of IPD.

17 We graphed predicted incidence rates of each outcome among under-vaccinated children under five at each
18 decile of PCV coverage, accounting for the balance of covariates across all the individuals [25]. We also
19 calculated the estimated population preventable fraction of PCV7-type IPD and all-cause pneumonia
20 hospitalisations for each decile of PCV coverage, defined as the proportion of disease among under-vaccinated
21 children estimated to be preventable by increasing vaccine coverage among different age groups [26].

22 We conducted subgroup analyses, examining PCV7-type IPD and all-cause pneumonia hospitalisations among
23 (1) children too young to be vaccinated (under four months of age); (2) under-vaccinated children in urban and
24 rural Australia; and (3) under-vaccinated Indigenous children. We expected that associations for these
25 subgroups may vary as the relationship between PCV coverage and pneumococcal disease is modulated by the
26 dynamics of pneumococcal transmission, which in turn differs with population density, age group, risk factors
27 and household structure [12,27].

28 Statistical analyses were performed according to a prospective data analysis plan (see S1 Text, Protocol).

29 Ethical approval was obtained from: The Aboriginal Health and Medical Research Council Ethics Committee
30 (approval ID: 931/13), AIHW Ethics Committee (approval ID: EC 2012/4/62), Department of Health Human
31 Research Ethics Committee (approval ID: 1/2013), Department of Health - WA Human Research Ethics
32 Committee (approval ID: 2012/75), NSW Population and Health Service Research Ethics Commit- tee
33 (approval ID: HREC/13/CIPHS/15), and Western Australian Aboriginal Health Ethics Committee (approval
34 ID: 459).

1 Results

2 Study cohort and outcomes

3 The cohort comprised 1 365 893 singleton children born between January 2001 and December 2012, of which 1
 4 223 803 lived in urban areas, 106 470 lived in rural areas, and 66 484 were Indigenous [15,28]. During 5 852
 5 233 person-years of follow-up among children under five years of age, 1,427 cases of IPD were notified: 43.2%
 6 due to PCV7 serotypes, 28.4% due to PCV13-non-PCV7 serotypes, 17.7% due to non-PCV serotypes, and
 7 10.7% lacked serotype data. Over the same period, 34 757 children experienced at least one episode of
 8 pneumonia hospitalisation, of which 799 (2.3%) were coded as pneumococcal or lobar pneumonia. Children
 9 were under-vaccinated against any PCV during 1 823 401 person-years of follow-up (31.2% of total person-
 10 years), with 83% of this time in children who had received no PCV doses.

11 **Table 1: Cohort characteristics by Indigenous status, New South Wales and Western Australia, 2001-**
 12 **2012**

		Non-Indigenous, n (%), N=1 299 409	Indigenous, n(%), N=66 484
State of birth registration	New South Wales	993 936 (76.5)	45 551 (68.5)
	Western Australia	305 473 (25.5)	20 933 (31.5)
Sex	Male	668 021 (95.1)	34 284 (4.9)
	Female	631 388 (95.2)	32 200 (4.9)
Socioeconomic index	91-100% (least disadvantaged)	160 519 (12.4)	990 (1.5)
	76-90%	199 055 (15.3)	2 739 (4.1)
	26-75%	582 833 (44.9)	21 704 (32.7)
	11-75%	196 074 (15.1)	15 371 (23.1)
	0-10% (most disadvantaged)	126 124 (9.7)	21 996 (33.1)
	Missing	34 804 (2.7)	3 684 (5.5)
Remoteness index	Major cities (urban)	989 470 (76.2)	27 633 (42.6)
	Inner regional (urban)	189 454 (14.6)	17 246 (25.9)
	Outer regional (rural)	71 056 (5.5)	10 899 (16.4)
	Remote (rural)	13 681 (1.1)	4 813 (7.2)
	Very remote (rural)	3 310 (0.3)	2 711 (4.8)
	Missing	32 438 (2.5)	3 182 (4.8)
Number of previous pregnancies (parity)	0	520 276 (40.0)	22 119 (33.3)
	1	434 073 (33.4)	16 512 (24.8)
	2	205 396 (15.8)	11 002 (16.6)
	≥ 3	138 257 (10.6)	16 786 (25.3)
Birthweight (g)	<1500	7 105 (0.6)	833 (1.3)
	1500-2499	45 846 (3.5)	5 417 (8.2)
	2500-3499	668 358 (51.4)	36 029 (54.2)
	3500-4499	555 005 (42.7)	23 126 (34.8)
	≥4500	22 771 (1.8)	1 065 (1.6)
	Missing	324 (0.0)	14 (0.0)
Prematurity (gestational age < 33 weeks)	Preterm	8 539 (0.7)	993 (1.5)
	Missing	156 (0.0)	30 (0.1)
Parental smoking	Yes	151 309 (11.6)	30 309 (45.6)
	Missing	2890 (0.2)	81 (0.1)

Hospital admission aged < 6 weeks	193 020 (14.9)	13 566 (20.4)
Any hospital admission for risk condition	47 705 (3.7)	3 382 (5.1)

1

2 **Incidence of invasive pneumococcal disease (IPD) and pneumonia**

3 **hospitalisations by period**

4 Among under-vaccinated children, rates of all-cause IPD decreased from 73.3 in the targeted PCV7 period to
 5 17.1 per 100 000 person-years in the universal PCV13 period (Table 1). Rates of PCV13, non-PCV7-type IPD
 6 increased in the universal PCV7 period, before decreasing in the universal PCV13 period (Table 1). In the
 7 universal PCV7 period, rates of PCV7-type IPD were higher in under-vaccinated children compared to all
 8 children. Comparable trends were observed among different age groups and among both Indigenous and non-
 9 Indigenous children (S1 File, Table 4). Annual rates of PCV7 and PCV13, non PCV7-type IPD are presented
 10 alongside annual PCV coverage estimates in S1 File, Tables 6 and 7.

11 **Table 1: Rates of invasive pneumococcal disease (IPD) among all children and under-vaccinated**
 12 **children* by vaccination period, New South Wales and Western Australia, 2001-2012**

	All children		Under-vaccinated children (PCV13)	
	Cases/ person-years	IPD rate (95% CI) †	Cases/ person-years	IPD rate†
All-cause IPD				
Targeted PCV7 (2001-04)	603/835 128	7.2 (6.7-7.8)	595/811 740	7.3 (6.7-7.9)
Universal PCV7 (2005-10)	595/3 275 465	1.8 (1.7-2.0)	181/944 751	1.9 (1.7-2.2)
Universal PCV13 (2011-12)	225/1 741 640	1.3 (1.2-1.5)	30/175 044	1.7 (1.2-2.5)
PCV7-type IPD				
Targeted PCV7 (2001-04)	460/835 333	5.5 (5.0-6.0)	455/811 919	5.6 (5.1-6.1)
Universal PCV7 (2005-10)	144/3 276 676	0.4 (0.4-0.5)	103/945 020	1.1 (0.9-1.3)
Universal PCV13 (2011-12)	13/1 742 423	0.1 (0.0-0.1)	3/175 090	0.2 (0.1-0.5)
PCV13, non-PCV7-type IPD				
Targeted PCV7 (2001-04)	29/833 868	0.4 (0.2-0.5)	29/835 868	0.4 (0.2-0.5)
Universal PCV7 (2005-10)	265/3 277 575	0.8 (0.7-0.9)	265/3 277 444	0.8 (0.7-0.9)
Universal PCV13 (2011-12)	111/1 741 984	0.6 (0.5-0.8)	101/1 282 026	0.8 (0.7-1.0)

13 * Under-vaccinated for both PCV7 and PCV13; † per 10 000 person-years

14 Among under-vaccinated children, rates of all-cause pneumonia decreased from 90.7 to 50.3 per 10 000 person-
 15 years from targeted PCV7 to universal PCV13 periods (Table 2). Substantial reductions were observed for both
 16 all-cause pneumonia and pneumococcal or lobar pneumonia across different age groups by vaccination period
 17 (S1 File, Table 5).


1 **Table 2: Rates of pneumonia hospitalisations among all children and under-vaccinated children*, New**
 2 **South Wales and Western Australia by vaccination period, 2001-2012**

	All children		Under-vaccinated children (PCV13)	
	Cases/ person-years	Hospitalisation rate† (CI)	Cases/ person-years	Hospitalisation rate† (CI)
All-cause pneumonia hospitalisations				
Targeted PCV7 (2001-04)	7 704/811 760	94.9 (92.8-97.0)	7 156/788 957	90.7 (88.6-92.8)
Universal PCV7 (2005-10)	18 026/3 229 066	55.8 (55.0-56.6)	4 589/931 337	49.3 (47.9-50.7)
Universal PCV13 (2011-12)	9 009/1 720 705	52.4 (51.3-53.4)	876/174 256	50.3 (47.0-53.7)
Pneumococcal or lobar pneumonia hospitalisations				
Targeted PCV7 (2001-04)	284/820 697	3.5 (3.1-3.9)	266/812 094	3.3 (2.9-3.7)
Universal PCV7 (2005-10)	364/3 275 939	1.1 (1.0-1.2)	100/945 250	1.1 (0.9-1.3)
Universal PCV13 (2011-12)	158/1 744 642	0.9 (0.8-1.1)	18/175 070	1.0 (0.6-1.6)

3 * Under-vaccinated for both PCV7 and PCV13; † per 10 000 person-years

4 **PCV coverage**


5 Among children under five years, coverage of any PCV increased steeply to 40% reflecting a catch-up program
 6 up to two years of age, then more gradually over the next four years as vaccinated children aged into older age
 7 groups, reaching 86% by December 2012.



8
 9 **Fig 1: Quarterly coverage* of any pneumococcal conjugate vaccine (PCV) and 13-valent PCV (PCV13)**
 10 **among children under five years of age, New South Wales and Western Australia, 2001-2012**

1 *Vaccinated defined as two or more PCV doses administered at < 12 months of age, or at least one PCV dose
2 administered after the age of 12 months

3 Figs 2 and 3 depict the geographical heterogeneity in PCV coverage at the SLA level among children aged 12-
4 23 months at the end of each of the following years: 2005, 2009 and 2012, with greatest heterogeneity in the
5 year of universal PCV introduction (2005). The median and interquartile ranges of SLA-level PCV coverage in
6 both age categories by year are presented in S1 File, Tables 6 and 7.




7

8 **Fig 2: Coverage* of any pneumococcal conjugate vaccine among children less than five years of age by**
9 **statistical local area (SLA) and year, New South Wales, 2001-2012; top row: New South Wales (state),**
10 **bottom row: Sydney (capital city); SLAs coloured white have been excluded due to small numbers of**
11 **children**

12 *Vaccinated defined as two or more PCV doses administered at < 12 months of age, or at least one PCV dose
13 administered after the age of 12 months

14 Statistical Local Area Digital Boundaries (ASGC 2006) obtained from the Australian Bureau of Statistics
15 (<https://www.abs.gov.au/>) CC BY 4.0

16



1

2 **Fig 3: Coverage* of any pneumococcal conjugate vaccine among children 12-23 months of age by**
3 **statistical local area and year, Western Australia, 2001-2012; top row: Western Australia (state), bottom**
4 **row: Perth (capital city); SLAs coloured white have been excluded due to small numbers of children**

5 *Vaccinated defined as two or more PCV doses administered at < 12 months of age, or at least one PCV dose
6 administered after the age of 12 months

7 Statistical Local Area Digital Boundaries (ASGC 2006) obtained from the Australian Bureau of Statistics


8 (<https://www.abs.gov.au/>) CC BY 4.0

9 **PCV coverage and indirect protection against vaccine-type IPD**

10 Fig 4 shows the association between PCV coverage and incidence of PCV7-type IPD for under-vaccinated
11 children aged under five years. The number of IPD cases and the under-vaccinated person time available for
12 analysis at different levels of PCV coverage are provided in S1 File, Table 8.

13 For each percentage point increase in PCV coverage among children 0-59 months of age, the adjusted
14 incidence of PCV7-type IPD decreased by 3.3% (95% CI 2.5-4.2, <0.001) among under-vaccinated children
15 under five years of age (S1 File, Table 10). The steepest declines in PCV7-type IPD occurred between 0% and
16 50% coverage among children 0-59 months of age (Fig 4).


17 Additionally, there was a trend towards decreasing incidence of PCV13-type IPD among under-vaccinated
18 children as PCV13 coverage increased, however confidence intervals were wide (adjusted incidence rate ratio
19 [aIRR] 0.989; 95% CI 0.971-1.007; p=0.241). (Fig 4 and S1 File, Table 10).



1

2 **Fig 4: Estimated rate of vaccine-type invasive pneumococcal disease incidence* and 95% confidence**
 3 **intervals (blue shading) among under-vaccinated children under five years, at each decile of**
 4 **pneumococcal conjugate vaccine (PCV) coverage, New South Wales and Western Australia, 2001-12.**
 5 ***PCV13, non-PCV7-type IPD incidence was only estimated up to 60% as there were few data points**
 6 **available**

7 Subgroup analyses among children less than four months of age, children living in urban areas, children living
 8 in rural areas and Indigenous children showed similar trends, although confidence intervals for Indigenous and
 9 rural subgroup analyses were wide as sample sizes were small (see Fig 5 and S1 File, Table 12).



10

11 **Fig 5: Estimated rate of vaccine-type invasive pneumococcal disease incidence* and 95% confidence**
 12 **intervals (blue shading) among three subgroups of under-vaccinated children under five years (urban,**
 13 **rural and Indigenous), at each decile of pneumococcal conjugate vaccine (PCV) coverage, New South**
 14 **Wales and Western Australia, 2001-12.**

1 Table 3 shows the estimated preventable fraction of PCV7-type IPD in under-vaccinated children less than five
2 years of age for each decile increase in PCV coverage. Vaccinating half of children less than five years of age
3 is estimated to prevent 81.4% (95% CI 71.2-88.0) of PCV7-type IPD, while 90% coverage prevents 95.2%
4 (95% CI 89.4-97.8).


5 **Table 3: Preventable fraction of PCV7-type IPD in under-vaccinated children under five years at deciles**
6 **of pneumococcal conjugate vaccine (PCV) coverage, New South Wales and Western Australia, 2001-2012**

Coverage (%)	Preventable fraction of PCV7-type IPD at deciles of PCV coverage
10	28.6 (22.1-34.6)
20	49.0 (39.2-57.2)
30	63.6 (52.6-72.0)
40	74.0 (63.1-81.7)
50	81.4 (71.2-88.0)
60	86.7 (77.6-92.2)
70	90.5 (82.5-94.9)
80	93.2 (86.4-96.6)
90	95.2 (89.4-97.8)

7

8 **PCV coverage and indirect protection against pneumonia** 9 **hospitalisations**

10 Similarly, there were inverse associations between PCV coverage and incidence of both all-cause pneumonia
11 and pneumococcal or lobar pneumonia hospitalisations among under-vaccinated children (Fig 6 and S1 File,
12 Table 11). The number of pneumonia hospitalisations and under-vaccinated person-time at the different levels
13 of PCV coverage are provided in S1 File, Table 9. For each percentage point increase in PCV coverage among
14 children less than five years of age, the adjusted incidence of pneumococcal or lobar pneumonia
15 hospitalisations decreased by approximately 1.5% (95% CI 0.7-2.6; p=0.001) (S1 File, Table 11). For each
16 percentage point increase in PCV coverage among children 0-59 months of age, the adjusted incidence of all-
17 cause pneumonia hospitalisations decreased by approximately 0.9% (95% CI 0.6-1.0; p<0.001) (S1 File, Table
18 11).



1

2 **Fig 6: Estimated rate of pneumonia hospitalisation and 95% confidence intervals (blue shading) among**
 3 **under-vaccinated children at each decile of pneumococcal conjugate vaccine (PCV) coverage, New South**
 4 **Wales and South Australia, 2001-12.**

5 Subgroup analyses for all-cause pneumonia hospitalisations among children living in urban areas, children
 6 living in rural areas and Indigenous children showed similar trends, although again confidence intervals for
 7 Indigenous and rural subgroup analyses were wide as there were fewer cases and individuals in these subgroups
 8 (S1 File, Table 13).

9 Table 4 shows the preventable fraction of all-cause pneumonia hospitalisations in under-vaccinated children
 10 less than five years of age by each decile increase in PCV coverage. We estimate that vaccinating 50% of
 11 children less than five years of age will prevent 33.3% (95% CI 27.3-38.8) of all-cause pneumonia
 12 hospitalisations in under-vaccinated children less than five years, while vaccinating 90% prevents 51.7% (95%
 13 CI 43.7-58.6).

14 **Table 4 Preventable fraction of all-cause pneumonia hospitalisations in under-vaccinated children under**
 15 **five years at deciles of pneumococcal conjugate vaccine (PCV) coverage, New South Wales and Western**
 16 **Australia, 2001-2012**

Coverage (%)	Preventable fraction of all-cause pneumonia hospitalisation at deciles of PCV coverage
10	7.7 (6.2-9.3)
20	14.9 (11.9-17.8)
30	21.6 (17.4-25.5)
40	27.6 (22.5-32.4)
50	33.3 (27.3-38.8)
60	38.4 (31.8-44.5)
70	43.2 (36.0-49.7)
80	47.7 (40.0-54.4)
90	51.7 (43.7-58.6)

1

2 **Discussion**

3 Our novel analyses highlight the relatively low levels of coverage required to generate indirect protection in
4 children against IPD and pneumonia hospitalisations in Australia. These results challenge pre-existing ideas
5 that high coverage is required for substantial indirect protection. Consistent with previous studies, we
6 demonstrated an inverse relationship between PCV coverage and indirect effects on vaccine-type IPD [29]. A
7 meta-analysis of PCV impact studies reported a 0.5% reduction in IPD (95% credible interval 0.2- 1.1%)
8 among children and adults for each percentage increase in vaccine coverage among children, accounting for
9 country-level confounders [30]. However, in contrast to previous pneumococcal carriage studies, which
10 reported statistically significant indirect effects at 58-75% coverage, we identified substantial indirect effects at
11 lower rates of PCV coverage [21,22,31]. While not directly comparable, the indirect effect of PCV against
12 disease can be expected to reflect indirect effects on carriage, since these effects are mediated by reductions in
13 carriage.[23] The variation in results may be due to differences in analytic method. Compared to annual
14 carriage surveys conducted by Hammitt et al. [31], we analysed at quarterly intervals allowing us to detect
15 indirect effects at lower coverage rates. Grant et al. defined indirect effects as a statistically significant
16 reduction in vaccine-type carriage prevalence, a measure which depends on both the effect size and sample size
17 [22]. While Loughlin et al. chose to define indirect effects *a priori* as a 50% decline in vaccine-type carriage
18 [21]. By modelling the association, we were able to quantify degree of indirect effects at varying coverage
19 rates, facilitating future comparisons between studies with varying sample sizes and methods. Differences in
20 the relationship between PCV coverage and indirect effects between studies may also be due to differences in
21 the vaccine type studied (i.e. PCV7, PCV10 or PCV13) or context.

22 Importantly, we found similar trends among rural populations and Indigenous populations, although these
23 effects were smaller and had large confidence intervals which likely reflects the smaller sample size available
24 for analysis. These findings are important as they reflect indirect effects in different settings with different
25 patterns of social mixing and therefore patterns of pneumococcal disease transmission. The modelled incidence
26 of PCV7-type disease at zero coverage was lower than expected, given Indigenous children are known to be at
27 high risk of pneumococcal disease. This is likely due to the earlier introduction of PCV for Indigenous children
28 in 2001, which meant under-vaccinated Indigenous children were already benefiting from some degree of
29 indirect effects at the start of our study's observation period. Without sufficient baseline data prior to vaccine
30 introduction, our analyses likely underestimate the full extent of indirect effects among Indigenous children.
31 Given that Indigenous children make up 17.3% of our rural cohort, the earlier introduction of PCV among
32 Indigenous children may also have impacted on our estimates of indirect effects in rural settings. However, the
33 low baseline rates of disease may also be attributable to a more sparsely populated rural population with less
34 social mixing compared to urban settings [32]. Previous studies on the direct effect of PCV, found the vaccine
35 to be equally effective among Indigenous children and children from rural areas, suggesting that our results are
36 not due to reduced vaccine effectiveness in these groups. . Evidence of indirect effects among children under

1 four months of age, albeit not statistically significant, is also important to note since these children are too
2 young to be fully vaccinated across the time period while vaccine eligibility and coverage changes for other age
3 groups.

4 Our analyses also demonstrated increasing indirect protection against pneumonia hospitalisations with rising
5 PCV coverage. Pneumonia comprises a substantially larger disease burden than IPD and is a crucial
6 determinant of vaccine cost-effectiveness of a PCV program. Our findings are consistent with previous analysis
7 using the same dataset, which found 38% and 28% reductions in all-cause pneumonia hospitalisations among
8 children <2 and 2-4 years of age, respectively, two years post-PCV7 introduction in Australia [33]. Similar
9 relationships have been reported for PCV uptake and pneumonia hospitalisations in Brazil [29]. While our
10 analyses, accounted for individual-level risk factors for pneumonia, it did not account for temporal trends,
11 including changes admission practices or pneumonia epidemiology, which could account for an overall decline
12 in pneumonia across this time period. This may explain the unexpectedly large estimate that over 50% of all-
13 cause pneumonia among under-vaccinated children is preventable at 90% PCV coverage among children under
14 five.

15 Our analyses did not identify a clear threshold at which PCV7-type IPD was eliminated – with 5% of PCV7-
16 type remaining at 90% coverage. Similarly, a prior study of the long-term impacts of PCV against IPD in
17 Australia reported reductions of 98% and 96% in vaccine-type IPD among children <2 and 2-4 years old eight
18 years after vaccine introduction [3]. Our results may reflect the inherent limitations of the vaccine or schedule
19 or insufficient period of monitoring post-PCV introduction to see full vaccine impacts; alternatively there may
20 be a lag in observing the full effects of indirect protection after reaching a certain PCV coverage [8], which was
21 not accounted for in this model.

22 While our analyses of PCV7-type IPD showed the steep declines in disease, especially up to 50% PCV
23 coverage, we observed flatter associations between PCV coverage and both PCV13-type IPD and all-cause
24 pneumonia hospitalisations. These results are consistent with previous studies indicating higher coverage rates
25 (58-75) were required for substantial indirect effects using PCV10 and PCV13. This may be explained by
26 previous research indicating lower vaccine effectiveness against the additional serotypes in PCV13[34,35].
27 However, there is a high degree of uncertainty around our PCV13 estimates since we have limited data post-
28 PCV13 introduction (1.5 years) and a small number of PCV13, non-PCV7 type IPD cases. At the end of our
29 study period, PCV13 coverage had only reached a median of 32.1% among children under five. Therefore our
30 analyses are unable to capture the full indirect effects of PCV13, which are likely to increase as vaccine
31 coverage rises over time. Smaller effect sizes for the indirect vaccine effects against all-cause pneumonia
32 hospitalisations may be due to the non-specific nature of the outcome and/or differences in vaccine efficacy
33 against the different spectrum of serotypes causing pneumonia, compared to IPD [36].

34 The availability of a large population-based linked dataset and analyses at fine spatial and temporal resolutions
35 enabled precise evaluation of indirect effects in Australia, however there are some limitations. While our cohort
36 is estimated to represent 97.5% of live births, it does not include children who have migrated into the two states

1 or children who were never registered at birth. SLA of residence was based on the mother's SLA of residence
2 at the time of the child's birth and we do not have updated data on SLA of residence if a family or child moved.
3 We acknowledge that SLAs will not perfectly capture the boundaries of communities which interact socially, in
4 which to measure indirect protection. As with all observational studies, causation cannot be assured. However,
5 we observed a "dose effect" of PCV- for each decile increase in coverage there was a decline in pneumococcal
6 disease and with the exception of parental smoking, the prevalence of measured confounders changed very little
7 over time. Our definition of under-vaccinated included children who received one dose of vaccine under 12
8 months of age who may benefit from some direct protection, however majority of under-vaccinated person-
9 time was in children who had no doses (83%) and sensitivity analyses among completely unvaccinated children
10 yielded similar results [37,38]. We consider the risk of misclassification of vaccination status to be low, since
11 vaccination status was determined using an immunisation registry, which has previously been demonstrated to
12 underestimate coverage by less than 5% [39]. Lastly, an important limitation of this study is the potential for
13 loss to follow-up in children who have moved interstate (missing outcome data) or overseas (missing
14 vaccination and outcome data). From 2001 to 2012, the annual interstate out-migration of children less than
15 five years of age ranged from 1.6-2.2% in New South Wales and 1.4-2.1% in Western Australia [40]. Data
16 available from 2004-2012 indicates that overseas out-migration was less common, ranging from 0.9-1.2% [41].
17 Since our analyses are for children up to five years of age, we estimate that the cumulative unobserved loss to
18 follow-up time to be less than 15% - in line with recommendations for cohort [42]. Furthermore, we do not
19 expect differential loss to follow-up between vaccinated and under-vaccinated children or as vaccine coverage
20 rises over time, since migration patterns have remained constant.

21 Our results support continuing efforts to increase vaccine coverage to maximise indirect protection from PCV
22 in Australia. In our study, PCV7-type IPD continue to decline as coverage increases among children under five
23 years, suggesting that catch-up vaccination up to five years of age may be important to maximise indirect
24 effects – in line with previous research [43]. Indirect protection is important because it comprises a substantial
25 component of overall impact, improves cost-effectiveness of the vaccine and protects infants too young to be
26 vaccinated and adults. While our study does not include indirect effects on adult disease, prior research
27 suggests that in low-transmission settings indirect effects in children are effectively translated to indirect effects
28 in adults, since children are the primary drivers of pneumococcal transmission [44,45].

29 Understanding the coverage required to achieve indirect protection is of considerable global interest in the
30 potential for reduced dose (1+1) schedules [6] as the success of this program relies on the continued generation
31 of indirect protection for infants who have not received sufficient doses to mount individual level protection
32 [6]. Our findings suggest that lower rates of vaccine coverage may still be confer considerable indirect effects
33 and therefore a 1+1 schedule may be suitable despite low coverage PCV coverage. Additionally, we found
34 evidence that these trends are similar across a range of subgroups. However, our findings cannot be directly
35 extrapolated to other settings since degree of indirect protection is highly dependent on local factors influencing
36 pneumococcal transmission [27]. Other studies have demonstrated lower than expected direct and indirect
37 effects following PCV13 introduction in Australia, which used a 3+0 schedule, compared to countries using a

1 booster dose, such as the UK (2+1 schedule) and US (3+1 schedule) [16,46]. As a result, Australia
2 implemented a switch from the 3+0 to 2+1 schedule in 2018. Further research beyond the timeframes available
3 in this analysis is needed to document the longer-term impacts of PCV13 introduction and the schedule change
4 on indirect effects in Australia. Further research, using consistent and robust methodology, is also required to
5 understand the relationship between PCV coverage and indirect protection in a range of settings, particularly in
6 high-transmission settings. This will assist with understanding the role of PCV coverage as an alternative
7 metric to determine if indirect effects are present in settings with insufficient disease surveillance.

8 **Contributors**

9 FMR and JC conceptualised and designed the study. JC performed the analysis and drafted the initial
10 manuscript. CDN provided expert statistical advice. PF and HFG assembled the cohort used for the
11 pneumococcal analyses. HFG, PBM, CB, PF, HM, KM, and RA provided expert clinical and epidemiological
12 advice, and assisted with the interpretation and presentation of results. All authors reviewed and revised the
13 manuscript and approved the submitted final manuscript.

14 **Funding**

15 This study was funded by the Population Health Research Network Proof of Concept Project, a capability of the
16 Commonwealth Government Collaborative Research Infrastructure Strategy and Education Investment Fund
17 Super Science Initiative, and the Australian National Health and Medical Research Council (project grant
18 GNT1082342, chief investigator HFG). HFG, CCB, HCM and FMR are funded by Australian National Health
19 and Medical Research Council (NHMRC) fellowships. Specifically, FMR is funded by an NHMRC Translating
20 Research into Practice (TRIP) fellowship and Investigator grant. JC is funded by the Australian Research
21 Training Program scholarship. HCM is further supported by a Telethon Kids Institute Emerging Research
22 Leader Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or
23 preparation of the manuscript.

24 **Acknowledgements**

25 We thank the staff at the Population Health Research Network (PHRN), participating PHRN data linkage and
26 infrastructure nodes (the Western Australian Data Linkage Branch, the New South Wales Centre for Health
27 Record Linkage, and the Australian Institute for Health and Welfare), the Western Australia and
28 Commonwealth Departments of Health and New South Wales Ministry of Health who provided advice and the
29 data, and the Aboriginal and Torres Strait Islander community and members of the Aboriginal Immunisation
30 Reference Group for their contribution to this research project.

31 **References**

32 1. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus
33 pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines:

- 1 global, regional, and national estimates for 2000–15. *The Lancet Global Health*. 2018;6: e744–e757.
2 doi:10.1016/S2214-109X(18)30247-X
- 3 2. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O’Brien KL. The fundamental link between
4 pneumococcal carriage and disease. *Expert Rev Vaccines*. 2012/08/24 ed. 2012;11: 841–855.
5 doi:10.1586/erv.12.53
- 6 3. Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, et al. Long-term impact of a “3+0”
7 schedule for 7 and 13 valent pneumococcal conjugate vaccines on invasive pneumococcal disease in
8 Australia, 2002-2014. *Clinical Infectious Diseases*. 2016. doi:10.1093/cid/ciw720
- 9 4. Pilishvili T, Gierke R, Farley M, Schaffner W, Thomas A, Reingold A, et al. Direct and Indirect Impact
10 of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD)
11 Among Children and Adults in the U.S. *Open Forum Infectious Diseases*. 2017;4: S66–S67.
12 doi:10.1093/ofid/ofx162.158
- 13 5. Weinberger R, von Kries R, van der Linden M, Rieck T, Siedler A, Falkenhorst G. Invasive
14 pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the
15 maximum effect of PCV13 in 2012/13 in Germany. *Vaccine*. 2018;36: 572–577.
16 doi:10.1016/j.vaccine.2017.11.085
- 17 6. Flasche S, Van Hoek AJ, Goldblatt D, Edmunds WJ, O’Brien KL, Scott JAG, et al. The Potential for
18 Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in
19 High-Income Countries. *PLOS Medicine*. 2015;12: e1001839. doi:10.1371/journal.pmed.1001839
- 20 7. Health England P. Vaccine update issue 303 - PCV special edition December 2019. 2019.
- 21 8. Fine P, Eames K, Heymann DL. “Herd Immunity”: A Rough Guide. *Clinical Infectious*
22 *Diseases*. 2011;52: 911–916. doi:10.1093/cid/cir007
- 23 9. Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines
24 introduction: A systematic review of the literature. *Vaccine*. 2017;35: 2882–2891.
25 doi:10.1016/j.vaccine.2017.04.032
- 26 10. International Vaccine Access Center (IVAC) - Johns Hopkins Bloomberg School of Public Health.
27 VIEW-hub. 2018 [cited 11 Nov 2018]. Available: <http://view-hub.org/viz/>
- 28 11. Mcnamara B, Gubhaju L, Jorm L, Preen D, Jones J, Joshy G, et al. Exploring factors impacting early
29 childhood health among Aboriginal and Torres Strait Islander families and communities: protocol for a
30 population-based cohort study using data linkage (the “Defying the Odds” study). *BMJ Open*. 2018;8:
31 21236. doi:10.1136/bmjopen-2017-021236
- 32 12. Eades S. Pneumococcal vaccination in Australian children: divergent outcomes. *The Lancet Child &*
33 *Adolescent Health*. 2019. doi:10.1016/S2352-4642(19)30264-0
- 34 13. Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. Invasive pneumococcal disease in central
35 Australia. *Medical Journal of Australia*. 1995;162: 182–186. doi:10.5694/j.1326-5377.1995.tb126016a.x
- 36 14. National Centre for Immunisation Research and Surveillance (NCIRS). History of vaccination in
37 Australia. 2018. Available: <http://www.ncirs.edu.au/provider-resources/vaccination-history/>
- 38 15. Fathima P, Gidding HF, McIntyre PB, Snelling TL, McCallum L, de Klerk N, et al. Effectiveness of
39 pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a
40 retrospective, population-based, record-linked cohort study. *The Lancet Child & Adolescent Health*.
41 2019;0. doi:10.1016/S2352-4642(19)30249-4
- 42 16. Blyth CC, Jayasinghe S, Andrews RM. A Rationale for Change: An Increase in Invasive Pneumococcal
43 Disease in Fully Vaccinated Children. *Clinical Infectious Diseases*. 2019. doi:10.1093/cid/ciz493

- 1 17. Gidding HF, McCallum L, Fathima P, Snelling T, Liu B, De Klerk N, et al. Probabilistic linkage of
2 national immunisation and state-based health records for a cohort of 1.9 million births to evaluate
3 Australia's childhood immunisation program. *International Journal for Population Data Science*. 2017;2.
4 doi:10.23889/ijpds.v2i1.406
- 5 18. Moore HC, Guiver T, Woollacott A, de Klerk N, Gidding HF. Establishing a process for conducting
6 cross-jurisdictional record linkage in Australia. *Aust N Z J Public Health*. 2015/11/13 ed. 2016;40: 159–
7 164. doi:10.1111/1753-6405.12481
- 8 19. Fathima P, Blyth CC, Lehmann D, Lim FJ, Abdalla T, de Klerk N, et al. The Impact of Pneumococcal
9 Vaccination on Bacterial and Viral Pneumonia in Western Australian Children: Record Linkage Cohort
10 Study of 469589 Births, 1996–2012. *Clin Infect Dis*. 2017/10/27 ed. 2018;66: 1075–1085.
11 doi:10.1093/cid/cix923
- 12 20. Scott P, Rutjes AWS, Bermetz L, Robert N, Scott S, Lourenço T, et al. Comparing pneumococcal
13 conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysis.
14 *Vaccine*. 2011;29: 9711–9721. doi:10.1016/j.vaccine.2011.07.042
- 15 21. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and Indirect Effects of PCV13 on
16 Nasopharyngeal Carriage of PCV13 Unique Pneumococcal Serotypes in Massachusetts' Children. *The*
17 *Pediatric Infectious Disease Journal*. 2014;33: 504–510. doi:10.1097/INF.0000000000000279
- 18 22. Grant LR, Hammitt LL, O'Brien SE, Jacobs MR, Donaldson C, Weatherholtz RC, et al. Impact of the 13-
19 Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians. *The*
20 *Pediatric infectious disease journal*. 2016;35: 907–14. doi:10.1097/INF.0000000000001207
- 21 23. Weinberger DM, Grant LR, Weatherholtz RC, Warren JL, O'Brien KL, Hammitt LL. Relating
22 Pneumococcal Carriage among Children to Disease Rates among Adults before and after the Introduction
23 of Conjugate Vaccines. *American Journal of Epidemiology*. 2016;183: 1055–1062.
24 doi:10.1093/aje/kwv283
- 25 24. Australian Bureau of Statistics. Changes to geographic areas between Censuses. 2016. Available:
26 [http://www.abs.gov.au/websitedbs/censushome.nsf/4a256353001af3ed4b2562bb00121564/e4514294830](http://www.abs.gov.au/websitedbs/censushome.nsf/4a256353001af3ed4b2562bb00121564/e45142948304157cca257a4b000a6126!OpenDocument)
27 [4157cca257a4b000a6126!OpenDocument](http://www.abs.gov.au/websitedbs/censushome.nsf/4a256353001af3ed4b2562bb00121564/e45142948304157cca257a4b000a6126!OpenDocument)
- 28 25. Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal
29 effects. *The Stata Journal*. 2012.
- 30 26. Newson RB. Attributable and Unattributable Risks and Fractions and other Scenario Comparisons. *The*
31 *Stata Journal: Promoting communications on statistics and Stata*. 2013;13: 672–698.
32 doi:10.1177/1536867X1301300402
- 33 27. Neal EFG, Flasche S, Nguyen CD, Ratu FT, Dunne EM, Koyamaibole L, et al. Associations between
34 ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in Fiji. *Vaccine*. 2019.
35 doi:10.1016/J.VACCINE.2019.10.030
- 36 28. Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, et al. Effectiveness of a 3 + 0
37 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of
38 1.4 million children in Australia. *Vaccine*. 2018/04/09 ed. 2018;36: 2650–2656.
39 doi:10.1016/j.vaccine.2018.03.058
- 40 29. Warren JL, Shioda K, Kürüm E, Schuck-Paim C, Lustig R, Taylor RJ, et al. Impact of Pneumococcal
41 Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil.
42 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*.
43 2017;65: 1813–1818. doi:10.1093/cid/cix638

- 1 30. Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, et al. Indirect effects of childhood
2 pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-
3 analysis. *The Lancet Global Health*. 2016;5: e51–e59. doi:10.1016/S2214-109X(16)30306-0
- 4 31. Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al. Population effect of 10-
5 valent pneumococcal conjugate vaccine on nasopharyngeal carriage of *Streptococcus pneumoniae* and
6 non-typeable *Haemophilus influenzae* in Kilifi, Kenya: findings from cross-sectional carriage studies. *The*
7 *Lancet Global Health*. 2014;2: e397–e405. doi:10.1016/S2214-109X(14)70224-4
- 8 32. Vito T, Singh GR, Davison B, Campbell PT, Lydeamore MJ, Robinson A, et al. Indigenous Australian
9 household structure: A simple data collection tool and implications for close contact transmission of
10 communicable diseases. *PeerJ*. 2017;2017: e3958–e3958. doi:10.7717/peerj.3958
- 11 33. Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the
12 introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia.
13 *Pediatr Infect Dis J*. 2010/07/01 ed. 2010;29: 607–612.
- 14 34. Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, et al. A post-hoc analysis of
15 serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical
16 community acquired pneumonia from a randomized clinical trial in the Netherlands. *Vaccine*. 2019;37:
17 4147–4154. doi:10.1016/j.vaccine.2019.05.065
- 18 35. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent
19 pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after
20 its introduction: An observational cohort study. *The Lancet Infectious Diseases*. 2015;15: 535–543.
21 doi:10.1016/S1473-3099(15)70044-7
- 22 36. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific
23 effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: A
24 postlicensure indirect cohort study. *The Lancet Infectious Diseases*. 2014;14: 839–846.
25 doi:10.1016/S1473-3099(14)70822-9
- 26 37. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-
27 valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control
28 study. *Lancet*. 2006/10/31 ed. 2006;368: 1495–1502. doi:10.1016/s0140-6736(06)69637-2
- 29 38. Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of Seven and Thirteen
30 Valent Pneumococcal Conjugate Vaccines in a Schedule without a Booster dose: a Ten Year
31 Observational Study. *Clinical Infectious Diseases*. 2018/02/23 ed. 2018;67: 367–374.
32 doi:10.1093/cid/ciy129
- 33 39. Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Immunisation coverage in Australia corrected for
34 under-reporting to the Australian Childhood Immunisation Register. *Australian and New Zealand Journal*
35 *of Public Health*. 2003;27: 533–538. doi:https://doi.org/10.1111/j.1467-842X.2003.tb00829.x
- 36 40. Australian Bureau of Statistics. Interstate Migration by States and Territories of Arrival and Departure by
37 Sex. [cited 25 May 2021]. Available:
38 https://stat.data.abs.gov.au/Index.aspx?DataSetCode=ABS_DEM_QIM
- 39 41. Australian Bureau of Statistics. Net overseas migration, Arrivals, departures and net, State/territory, Age
40 and sex - Calendar years, 2004 onwards. [cited 25 May 2021]. Available:
41 https://stat.data.abs.gov.au/Index.aspx?DataSetCode=NETOVERSEASMIGRATION_CY
- 42 42. Kristman V, Manno M, Côté P. Loss to follow-up in cohort studies: how much is too much? *Eur J*
43 *Epidemiol*. 2004;19: 751–760. doi:10.1023/b:ejep.0000036568.02655.f8

- 1 43. Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association between the Decline
2 in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization
3 in Toddlers and Preschool-Aged Children. *American Journal of Epidemiology*. Oxford University Press;
4 2019. pp. 160–168. doi:10.1093/aje/kwy219
- 5 44. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, et al. Indirect Effect of
6 Conjugate Vaccine on Adult Carriage of *Streptococcus pneumoniae* : An Explanation of Trends in
7 Invasive Pneumococcal Disease. *Journal of Infectious Diseases*. 2006;99508: 1487–1494.
- 8 45. Weinberger DM, Pitzer VE, Regev-yochay G, Givon-lavi N, Dagan R. Association Between the Decline
9 in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization
10 in Toddlers and Pre-School Aged Children. *American Journal of Epidemiology*. 2019;188: 160–168.
11 doi:10.1093/aje/kwy219
- 12 46. Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, et al. Long-term Impact of a “3 + 0”
13 Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in
14 Australia, 2002–2014. *Clin Infect Dis*. 2017;64: 175–183. doi:10.1093/cid/ciw720

15 **Supporting information**

16 S1 RECORD Checklist

17 S1 Text. Protocol

18 S1 File. Supplementary Methods and Additional Analyses